Phaseline

Companies › Nested Therapeutics

Nested Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NST-628
non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway
RAF1, MAP2K1Phase 1OncologyNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06326411NST-628Phase 1OncologyOncologyNov 2028

Targets

RAF1 (1) MAP2K1 (1)

Companies with the same targets

Roche Novartis Hanmi Pharmaceutical Company Erasca Bayer Day One Biopharmaceuticals Ipsen AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.